FDA Approves WINREVAIR — Merck Sharp & Dohme LLC

# FDA Approves Merck's WINREVAIR (sotatercept-csrk), Expanding Treatment Options in Pulmonary Hypertension Market Merck Sharp & Dohme LLC's FDA approval of WINREVAIR (sotatercept-csrk) on March 26, 2024, marks a significant addition to the pulmonary hypertension therapeutic landscape, potentially capturing market share from existing treatments and opening new revenue streams for the company. The approval positions Merck to compete in a growing specialty pharmaceutical segment, with sotatercept-csrk